Unlock full details of this profile with our free聽Lite听辫濒补苍!
Sign Up and Get Free AccessBrook Biotechnologies - About the company
Brook Biotechnologies is an unfunded company. It operates as a Developer of therapeutics for the treatment of infectious diseases. Brook Biotechnologies has not raised any funding yet. The company has 116 active competitors, including 33 funded and 21 that have exited. Its top competitors include companies like Insmed, Aridis Pharma and Eligo Bioscience.
Company Details
Developer of therapeutics for the treatment of infectious diseases. The company is working on the development of drugs and vaccines for Lyme Disease.
Key Metrics
Stage
Unfunded
Ranked
149th among
Similar Companies
&
Brook Biotechnologies's funding and investors
Brook Biotechnologies has not raised any funding rounds yet.
Access 秘密研究所 on any website
Our Google Chrome extension lets you view company details while browsing their websites
Brook Biotechnologies's Competitors and alternates
Top competitors of Brook Biotechnologies include Insmed, Aridis Pharma and Eligo Bioscience. Here is the list of Top 10 competitors of Brook Biotechnologies, ranked by 秘密研究所 score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | 秘密研究所 Score |
|---|---|---|---|---|---|
1st | Insmed 1999, Bridgewater (United States), Public | Developer of small molecule inhibitors for rare lung diseases | - | 62/100 | |
2nd | Aridis Pharma 2005, San Jose (United States), Public | Provider of human monoclonal antibodies against infectious diseases | $42.1M | , 听&补尘辫;听 | 59/100 |
3rd |  Eligo Bioscience 2014, Paris (France), Series B | Developer of microbiome gene therapies against infectious disease | $52.3M | Seventure Partners, Sanofi Ventures听&补尘辫;听 | 55/100 |
4th | MaaT Pharma 2014, Lyon (France), Public | Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases | $42.3M | 55/100 | |
5th | Evofem 2009, San Diego (United States), Acquired | Developer of therapeutics for reproductive care for women | $100M | 54/100 | |
6th | ILiAD Biotechnologies 2012, New York City (United States), Series D | Developer of immunity-inducing vaccine for the prevention and treatment of pertussis | $51.2M | 54/100 | |
7th | Basilea 1999, Basel (Switzerland), Public | Developer of antibiotics, antifungals, and oncology drugs for treating multiple diseases | - | 52/100 | |
8th |  Lodo Therapeutics 2015, New York City (United States), Acquired | Developer novel therapeutics to treat resistant infectious diseases and cancers using AI | $19.9M | 52/100 | |
9th | Prokarium 2012, Keele (United Kingdom), Series C | Oral vaccines by re-engineering Salmonella into an efficient vaccine platform for a variety of infectious diseases. | $61.6M | 51/100 | |
10th | Affinivax 2013, Cambridge (United States), Acquired | Developer of technology-based conjugate vaccines against infectious diseases | $359M | Rock Springs Capital, Foresite Capital听&补尘辫;听 | 50/100 |
149th |  Unfunded | Developer of therapeutics for the treatment of infectious diseases | - | - | - |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Brook Biotechnologies's competitors? Click to see the top ones
Brook Biotechnologies's Investments and acquisitions
Brook Biotechnologies has made no investments or acquisitions yet.
Reports related to Brook Biotechnologies
Here is the latest report on Brook Biotechnologies's sector:
View
Are you a Founder ?
FAQ's about Brook Biotechnologies
Explore our recently published companies
- Tenevia - Meylan based, 2012 founded, Unfunded company
- Chat Diagram - Singapore based, 2024 founded, Unfunded company
- BuildQ - Sacramento based, 2024 founded, Unfunded company
